Hippocratic AI has announced the successful close of its Series C financing round, raising $126 million at a $3.5 billion valuation. This brings its total funding to $404 million. The round was led by Avenir Growth with participation from key investors including CapitalG (Google’s growth fund), General Catalyst, Andreessen Horowitz (a16z), Kleiner Perkins, Premji Invest, as well as many notable healthcare systems. Hippocratic AI adds that, in just 15 months since commercialization, it has partnered with over 50 large health systems, payors and pharma clients across six countries, created over 1,000 clinical use-cases and completed over 115 million clinical patient interactions without any safety incidents.
Also Read: IntelePeer Launches SmartAnalytics Starter Pack to Enhance AI Integration in Healthcare Operations
The company has said its generative-AI agents are for non-diagnostic, patient-facing use only and cannot prescribe or diagnose, underlining its “do no harm” ethos. “Every call our agents make is a patient whose life we have helped to make healthier. What this capital allows us to do is touch more lives and help more people while staying true to our core values of ‘do no harm’ and ‘patients first’,” said co-founder and CEO Munjal Shah. This funding will let the company accelerate global deployments, further invest in its Polaris Safety Constellation Architecture, drive product innovation, and go after strategic M&A to extend its capabilities. Strong investor backing and rapid growth also reflect the industry’s pressing need to alleviate labour pressures, improving access to care with safe, scalable AI platforms.